Issues related to topical immunotherapy for the treatment of warts: A review of the literature
Keywords:
Topical immunotherapy, wartsAbstract
Immunotherapy has emerged as a critical therapeutic tool for the treatment of warts. Immunotherapy for warts is currently restricted to recalcitrant lesions. Conventional therapy is not working despite the fact that there are numerous immunotherapeutic agents available. A small number of regimens appear to be extremely effective. Furthermore, there is a scarcity of evidence-based research. Data on their efficiency topical immunotherapeutic modalities commonly used in the treatment have all been reported as effective treatment modalities for different types of warts. Furthermore, in the majority of cases, their safety and effectiveness have not been evaluated in double-blind, controlled clinical trials, making the reproducibility of many of the listed treatments difficult to analyze and a possible placebo effect difficult to rule out. The different types of immunotherapy for warts are mentioned in this report.References
Leiding, J. W. & Holland, S. M. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130:1030-48.
Scheinfeld, N. & Lehman, D. S. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12:5.
Kollipara, R. et al. Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. J Clin Med. 2015;4: 832-46.
Lipke, M. M. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-93.
Jenson, A. B., Kurman, R. J. & Lancaster, W. D. Tissue effects of and host response to human papillomavirus infection. Dermatol Clin. 1991;9:203-9.
Cardoso, J. C. & Calonje, E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:145-54.
Miller, D. J. & Strauch, R. J. Management of Cutaneous Warts of the Hand. J Hand Surg Am. 2015;40:2274-6.
Nofal, A., Salah, E., Nofal, E. & Yosef, A. Intralesional antigen immunotherapy for the treatment of warts: current concepts and future prospects. Am J Clin Dermatol. 2013;14:253-60.
Amirnia, M., Khodaeiani, E., Fouladi, D. F. & Masoudnia, S. Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: A randomized, placebo-controlled, double-blind clinical trial including an extra group of candidates for cryotherapy. J Dermatolog Treat. 2016;27:173-8.
Nofal, A., Nofal, E., Yosef, A. & Nofal, H. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. Int J Dermatol. 2015;54:667-71.
Berth-Jones, J., Mc Burney, A. & Hutchinson, P. E. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venereol. 1994;74:312-3.
Lane, P. R. & Hogan, D. J. Diphencyprone. J Am Acad Dermatol. 1988;19:364-5.
Orecchia, G., Douville, H., Santagostino, L. & Rabbiosi, G. Treatment of multiple relapsing warts with diphenciprone. Dermatologica. 1988;177:225-31.
Choi, M. H., Seo, S. H., Kim, I. H. & Son, S. W. Comparative study on the sustained efficacy of diphencyprone immunotherapy versus cryotherapy in viral warts. Pediatr Dermatol. 2008;25:398-9.
Stute, J., Hausen, B. M. & Schulz, K. H. [Diphenylcyclopropenone - a new strong contact sensitizer (author’s transl)]. Derm Beruf Umwelt. 1981;29:12-14.
Choi, Y., Kim, D. H., Jin, S. Y., Lee, A.-Y. & Lee, S. H. Topical immunotherapy with diphenylcyclopropenone is effective and preferred in the treatment of periungual warts. Ann Dermatol. 2013;25:434-9.
van der Steen, P., van de Kerkhof, P., der Kinderen, D., van Vlijmen, I. & Happle, R. Clinical and immunohistochemical responses of plantar warts to topical immunotherapy with diphenylcyclopropenone. J Dermatol. 1991;18:330-3.
Yoshizawa, Y., Kitamura, K. & Maibach, H. I. Successful immunotherapy of chronic nodular prurigo with topical dinitrochlorobenzene. Br J Dermatol. 1999; 141:387-9.
Wilkerson, M. G., Connor, T. H. & Wilkin, J. K. Dinitrochlorobenzene is inherently mutagenic in the presence of trace mutagenic contaminants. Arch Dermatol. 1988;124:396-8.
Lee, A. N. & Mallory, S. B. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. J Am Acad Dermatol. 19991;41;595-9.
Dall’ Oglio, F., Nasca, M. R., D’Agata, O. & Micali, G. Adult and paediatric contact immunotherapy with squaric acid dibutylester (SADBE) for recurrent, multiple, resistant, mucocutaneous anogenital warts. Sex Transm Infect. 2002;78:309-10.
Silverberg, J. I. & Silverberg, N. B. Adjunctive trichloroacetic acid therapy enhances squaric acid response to verruca vulgaris. J Drugs Dermatol. 2012;11:1228-30.
Pride, G. L. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med. 1990;35:384-7.
Reid, R. et al. Superficial laser vulvectomy. IV. Extended laser vaporization and adjunctive 5-fluorouracil therapy of human papillomavirus-associated vulvar disease. Obstet Gynecol. 1990;76:439-48.
Department of Dermatology Venereology and Leprosy, Rajah Muthiah Medical College & Hospital, Annamalai University, Chidambaram, India - 608002 & K, K. Efficacy of Intralesional 5- Fluorouracil in Recalcitrant Warts a study at Tertiary Care Centre. JMSCR.2019;7.
Edwards, L. et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134: 25-30.
Arican, O., Guneri, F., Bilgic, K. & Karaoglu, A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol. 2004;31:627-31.
Micali, G., Dall’Oglio, F. & Nasca, M. R. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat. 2003;14:233-6.
Imagawa, I. & Suzuki, H. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007;34:264-6.
Egawa, K. & Ono, T. Topical vitamin D3 derivatives for recalcitrant warts in three immunocompromised patients. Br J Dermatol. 2004;150:374-6.
Kavya, M., Shashikumar, B. M., Harish, M. R. & Shweta, B. P. Safety and Efficacy of Intralesional Vitamin D3 in Cutaneous Warts: An Open Uncontrolled Trial. J Cutan Aesthet Surg. 2017;10:90-4.
Raghukumar, S. et al. Intralesional Vitamin D3 Injection in the Treatment of Recalcitrant Warts: A Novel Proposition. J Cutan Med Surg. 2017;21:320-4.
Labandeira, J., Vázquez-Blanco, M., Paredes, C., Suárez-Penaranda, J. M. & Toribio, J. Efficacy of topical calcipotriol in the treatment of a giant viral wart. Pediatr Dermatol. 2005;22:375-6.
Rind, T., Oiso, N. & Kawada, A. Successful Treatment of Anogenital Wart with a Topical Vitamin D(3) Derivative in an Infant. Case Rep Dermatol. 2010;2:46-9.
Omura, Y. Clinical Significance of Human Papillomavirus Type 16 for Breast Cancer & Adenocarcinomas of Various Internal Organs and Alzheimer’s Brain with Increased β-amyloid (1-42); Combined Use of Optimal Doses of Vitamin D3 and Taurine 3 times/day Has Significant Beneficial Effects of Anti-Cancer, Anti-Ischemic Heart, and Memory & Other Brain Problems By Significant Urinary Excretion of Viruses, Bacteria, and Toxic Metals & Substances. Acupunct Electrother Res. 2016; 41:127-34.
Balaji, G. Sinecatechins: A better prospect for treating anogenital warts. Indian J Sex Transm Dis AIDS. 2014;35:75-6.
Schöfer, H. et al. Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults. Indian J Sex Transm Dis AIDS. 2017;28:1433-43.
Tyring, S. K. Sinecatechins: Effects on HPV-Induced Enzymes Involved in Inflammatory Mediator Generation. J Clin Aesthet Dermatol. 202;5:19-26.
Fantasia, H. C. Sinecatechins ointment 15% for the treatment of external genital warts. Nurs Womens Health. 2012;16:418-22.
Nguyen, H. P., Doan, H. Q., Brunell, D. J., Rady, P. & Tyring, S. K. Apoptotic gene expression in sinecatechins-treated external genital and perianal warts. Viral Immunol. 2014;27:556-8.
Stockfleth, E. & Meyer, T. The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts. Expert Opin Biol Ther. 2012;12:783-93.
Kenawy, S., Mohammed, G. F., Younes, S. & Elakhras, A. I. Evaluation of TNF-α serum level in patients with recalcitrant multiple common warts, treated by lipid garlic extract. Dermatol Ther. 2014;27: 272-7.
Silverberg, N. Garlic Cloves for Verruca Vulgaris. Pediatric Dermatology. 2022;19:183.
Rouf, R. et al. Antiviral potential of garlic (Allium sativum) and its organosulfur compounds: A systematic update of pre-clinical and clinical data. Trends Food Sci Technol. 2020;104:219-34.
Modem, S., Dicarlo, S. E. & Reddy, T. R. Fresh Garlic Extract Induces Growth Arrest and Morphological Differentiation of MCF7 Breast Cancer Cells. Genes Cancer. 2012;3: 177-86.
Hakimzadeh, H., Ghazanfari, T., Rahmati, B. & Naderimanesh, H. Cytotoxic effect of garlic extract and its fractions on Sk-mel3 melanoma cell line. Immunopharmacol Immunotoxicol. 2010;32:371-5.
Rao, A. R., Sadhana, A. S. & Goel, H. C. Inhibition of skin tumors in DMBA-induced complete carcinogenesis system in mice by garlic (Allium sativum). Indian J Exp Biol. 1990;28:405-8.
Nishino, H., Iwashima, A., Itakura, Y., Matsuura, H. & Fuwa, T. Antitumor-promoting activity of garlic extracts. Oncology. 1989;46:277-80.
Ng, K. T. P. et al. A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS One. 2012;7:e31655.
